Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 573
- 试验地点
- 1
- 主要终点
- Identify new blood markers of liver cancer
研究概览
简要总结
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
详细描述
Liver cancer is a deadly cancer that is typically hard to diagnose and treat. The currently used blood marker for the clinical diagnosis of liver cancer is alpha-feto protein (AFP), which misses 40-60% of patients with liver cancer because it lacks sufficient specificity and sensitivity. The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with AFP. The aim of this study is to identify new blood markers of liver cancer that can be used to increase the rate of accurate diagnosis of this malignancy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.
- •Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia.
- •Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.
排除标准
- •Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.
结局指标
主要结局
Identify new blood markers of liver cancer
时间窗: upto 12 months
Blood specimens collected through another protocol, Patients would have signed informed consent for that protocol, and agreed to have their blood specimens stored for future research such as this one.
次要结局
未报告次要终点
研究者
Samuel So
Lui Hac Minh Professor and Professor of Surgery
Stanford University